ANGO

Angiodynamics

• TipRanks·3h ago

  3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026

• TipRanks·05/13 14:48

  AngioDynamics announces two-year PRESERVE trial data

• Benzinga·05/13 13:06

  AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer

• PUBT·05/13 13:01

  AngioDynamics reports durable 2-year NanoKnife outcomes in PRESERVE prostate cancer trial

• Reuters·05/13 13:00

  ANGIODYNAMICS ANNOUNCES TWO-YEAR PRESERVE TRIAL DATA DEMONSTRATING DURABLE NANOKNIFE IRE SYSTEM OUTCOMES IN INTERMEDIATE-RISK PROSTATE CANCER

• TipRanks·04/23 22:05

  AngioDynamics Files Patent Suit to Protect Thrombectomy Technology

• Benzinga·04/23 21:43

  AngioDynamics Files Patent Infringement Lawsuit Against Endovascular Engineering On April 23, 2026; Seeks Damages And Equitable Relief In Lawsuit Against Endovascular Engineering

• Reuters·04/23 21:20

  ANGIODYNAMICS INC - SEEKS DAMAGES AND EQUITABLE RELIEF IN LAWSUIT AGAINST ENDOVASCULAR ENGINEERING - SEC FILING

• PUBT·04/23 21:09

  AngioDynamics sues Endovascular Engineering over alleged Hēlo Thrombectomy System patent infringement

• NASDAQ·04/08 00:05

  Freedom Broker Initiates Coverage of AngioDynamics (ANGO) with Buy Recommendation

• Dow Jones·04/07 13:35

  AngioDynamics Initiated at Buy by Freedom Broker

• Dow Jones·04/06 15:19

  AngioDynamics Is Maintained at Buy by Canaccord Genuity

• Dow Jones·04/06 15:19

  AngioDynamics Price Target Cut to $16.00/Share From $18.00 by Canaccord Genuity

• Benzinga·04/06 15:09

  Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

• TipRanks·04/06 13:46

  AngioDynamics initiated with a Buy at Freedom Broker